Updated:
PD Theranostics
Optimizing... Fine Dining experience PD Theranostics is developing AI guided algorithms for superior therapeutic decision making and truly personalized...
PD Theranostics
Optimizing... Fine Dining experience PD Theranostics is developing AI guided algorithms for superior therapeutic decision making and truly personalized medicine Learn More
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, New York, United States
Principals
Matthew Duffy
Chief Executive Officer
Patrick Gallagher
Co-Founder, Black Diamond Research; Board Director, BioSig Technologies
Mark Poznansky
Scientific Founder & Scientific Advisory Board Member
AnnMarie Sastry
Artificial Intelligence Team Lead
Sector focus
Frequently asked questions
Who runs investment decisions at PD Theranostics?
PD Theranostics does not operate as an investment firm making external capital-allocation decisions. Management is led by CEO Matthew Duffy and co-founder Patrick Gallagher, who are also managing partners at Laidlaw Venture Partners, an investment banking unit of Laidlaw & Company. Operational and development decisions appear to flow through the management team, with scientific guidance from Dr. Mark Poznansky's team at Massachusetts General Hospital.
Which sectors does PD Theranostics explicitly avoid?
No negative sector preferences have been publicly disclosed. The company's focus is on AI-enabled theranostics for oncology and infectious disease, with current programs limited to prostate cancer and diabetic foot ulcers. There is no indication of expansion beyond tissue-based AI diagnostics.
What is PD Theranostics' known posture on co-investments alongside external GPs?
PD Theranostics does not appear to make co-investments or fund commitments. The firm operates a research-stage diagnostic platform and has not disclosed any external investment activities. Its capital structure and funding partners remain private.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: